Climb Bio (CLYM) Total Current Liabilities (2020 - 2026)

Climb Bio has reported Total Current Liabilities for 7 years, with the latest figure at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 42.14% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (down 42.14% YoY), and the FY2025 full-year result was $7.0 million, up 41.63% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $4.1 million, down from $7.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $7.6 million in Q2 2022, with the low at $2.8 million in Q4 2023.
• Historically, Total Current Liabilities has averaged $5.0 million across 5 years, with a median of $4.9 million in 2024.
• Annual changes were most pronounced in 2023 — Total Current Liabilities tumbled 53.81% — and 2025, when it surged 138.51%.
• Climb Bio's Total Current Liabilities stood at $6.1 million in 2022, then tumbled by 53.53% to $2.8 million in 2023, then soared by 74.06% to $4.9 million in 2024, then jumped by 41.63% to $7.0 million in 2025, then slumped by 41.71% to $4.1 million in 2026.
• The last three Total Current Liabilities figures came in at $4.1 million (Q1 2026), $7.0 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.